SARTORIUS AG
ISIN: DE0007165607
WKN: 716560
13 May 2024 03:00PM

EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification

SARTORIUS AG · ISIN: DE0007165607 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1901531

EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification (news with additional features)

13.05.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 Göttingen, Germany | May 13, 2024

Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
 
  • Sartorius selected as preferred partner for development and commercialization of integrated and continuous biomanufacturing (ICB) platform
  • Modular platform will combine highest flexibility with standardization
  • ICB supports lower resource consumption and higher productivity, enabling more affordable patient care and sustainable bioprocessing
  • Collaboration demonstrates Sartorius’ leading position in the field of process intensification

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing. Selected as a preferred supplier, Sartorius will contribute its engineering and manufacturing expertise to commercialize ICB platforms based on prototypes developed by Sanofi. In return, Sanofi will grant Sartorius exclusive access to its know-how and patents related to the ICB platform.

Sartorius is committing to the rapid development of hardware, consumables and process automation for diverse applications and volumes from development to commercial scale. As part of the collaboration and license agreement, Sartorius will exclusively commercialize the ICB platform offering to customers worldwide.

“Technological innovation is crucial for biopharmaceutical companies to significantly reduce the cost of drug manufacturing - while improving the environmental footprint of their operations – and ultimately getting life-saving drugs to patients faster. As the biologics landscape becomes more diverse, teaming up with Sanofi is an excellent basis for developing a unique modular platform that combines flexibility with the advantages of intensified bioprocessing. This collaboration will help Sartorius to further expand its position as a leading company in the field of integrated and continuous bioprocessing,” said Jan Schäfer, Head of Separation Systems at Sartorius.

Integrated continuous biomanufacturing is an advanced approach to the production of biopharmaceuticals. The concept aims to maximize efficiency by enabling uninterrupted and steady materials flow, as opposed to traditional batch methods, and by integrating multiple unit operations into a lean process setup. ICB reduces the overall process footprint, leading to lower raw material and energy consumption, higher productivity, and less waste.

Sartorius offers a wide array of applications for process intensification in both upstream and downstream, ranging from high-throughput tools for process development to scalable, flexible manufacturing solutions.


A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe.

Visit our newsroom and follow Sartorius on LinkedIn.


Contact
Leona Malorny
Head of External Communications
+49 (0)551.308.4067
Leona.malorny@sartorius.com


 

Additional features:

File: 20240513_SAG_Media Release_Sartorius collaborates with Sanofi


13.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1901531

 
End of News EQS News Service

1901531  13.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1901531&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70 3.400,00
EBITDA1,2 405,00 495,80 636,70 1.134,26 1.410,40 962,70 955,00
EBITDA-Margin3 25,86 27,14 27,26 32,89 33,78 28,35 28,09
EBIT1,4 298,61 335,66 456,11 903,16 1.070,00 503,90 530,00
EBIT-Margin5 19,07 18,37 19,53 26,18 25,63 14,84 15,59
Net Profit (Loss)1 197,48 218,74 299,56 426,98 655,40 290,00 205,00
Net-Margin6 12,61 11,97 12,83 12,38 15,70 8,54 6,03
Cashflow1,7 244,52 377,19 511,53 865,81 734,20 853,60 880,00
Earnings per share8 2,56 3,06 4,37 8,08 9,57 4,94 2,90
Dividend per share8 0,61 0,35 0,70 1,25 1,43 0,73 0,73
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: -

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Sartorius ST
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
716560 DE0007165607 AG 14.676,48 Mio € 10.07.1990 Halten 9F3FHV2Q+JW
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
44,10 39,18 1,13 40,56 5,05 15,47 4,32
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
1,43 0,73 0,73 0,41%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
27.03.2025 18.04.2024 19.07.2024 17.10.2024 16.02.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+1,15%
176,40 €
ATH 834,00 €
-4,84% -12,84% -33,43% -32,80% +2.483,86%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL